Unknown

Dataset Information

0

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.


ABSTRACT: Small molecule immune checkpoint inhibitors targeting PD-1 and other pathways may offer advantages including ease of dosing, ability to manage immune-related adverse events (irAEs) due to their shorter pharmacokinetic exposure and opportunity to target more than one pathway for improving efficacy. Here we describe the identification and characterization of CA-170, an amino acid inspired small molecule inhibitor of PD-L1 and VISTA derived from the interface of PD-1 and PD-L1. CA-170 exhibited potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes. Observed blocking of PD-L1 signaling and binding to PD-L1 in the cellular context without preventing the assembly of PD-1:PD-L1 complex support the formation of a defective ternary complex as the mechanism of action of CA-170. Oral administration of CA-170 resulted in increased proliferation and activation of T cells in the tumor, and significant anti-tumor efficacy in a number of immunocompetent mouse tumor models either as a single agent or in combination with approved therapeutics. These results prompted the advancement of CA-170 to human clinical trials.

SUBMITTER: Sasikumar PG 

PROVIDER: S-EPMC8187357 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6695792 | biostudies-literature
| S-EPMC4966836 | biostudies-other
| S-EPMC8386121 | biostudies-literature
| S-EPMC8205422 | biostudies-literature
| S-EPMC6749627 | biostudies-literature
| S-EPMC6956385 | biostudies-literature
| S-EPMC7601245 | biostudies-literature
| S-EPMC5889101 | biostudies-literature
| S-EPMC4366640 | biostudies-literature
| S-EPMC6394491 | biostudies-literature